Insulet Co. (NASDAQ:PODD) Position Boosted by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. raised its holdings in shares of Insulet Co. (NASDAQ:PODD) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,400 shares of the medical instruments supplier’s stock after acquiring an additional 600 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Insulet were worth $7,153,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. QRG Capital Management Inc. purchased a new position in Insulet during the 3rd quarter valued at about $297,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Insulet by 30.1% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock valued at $2,192,000 after acquiring an additional 1,942 shares in the last quarter. Fisher Asset Management LLC grew its stake in Insulet by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after acquiring an additional 3,113 shares in the last quarter. Orion Portfolio Solutions LLC grew its stake in Insulet by 86.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after acquiring an additional 3,623 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. lifted its holdings in shares of Insulet by 5.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock valued at $35,708,000 after buying an additional 8,301 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PODD. BTIG Research lifted their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Canaccord Genuity Group lifted their price target on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a report on Friday, February 21st. TD Cowen lifted their price target on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Finally, JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $289.06.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $272.27 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business’s 50 day moving average is $274.01 and its two-hundred day moving average is $249.91. The company has a market cap of $19.10 billion, a P/E ratio of 47.02, a P/E/G ratio of 3.62 and a beta of 1.23. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, equities analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.